Evolving CAR-T Therapies to Shift Beyond Hematological Malignancies

• Comparing PK profiles in autoimmune diseases and hematological malignancies to uncover differences in exposure, persistence, and dosing strategies
• Highlighting how endpoints, patient selection, and lymphodepletion approaches differ in lupus and MS
• Exploring clinical safety data to enhance autologous CAR-T expansions beyond oncology

Speakers:

Matthias Will

Chief Development Officer

Autolus